IGF-DES dosing — why no established dose exists

The single most important dosing fact about DES is comparative. In the animal study that ranked the IGF-1 variants against each other, hypoglycemic potency ran IGF-I < long-IGF-I < R3IGF-I ≈ LR3IGF-I < des(1-3)IGF-I — DES at the top (PMID 9415072). Separately, des(1-3)IGF-I is described as roughly 10-fold more potent than IGF-I at stimulating hypertrophy and proliferation in cultured cells (PMID 8930132).

That ranking is why the most common dosing practice in community material — reusing figures cited for IGF-1 LR3 — is structurally unsound. The two analogs are not equipotent, and DES sits above LR3 on the measured endpoint. A number carried across between them is a number applied to the wrong molecule.

There is no human dosing literature. The published amounts come from characterisation studies in animals (PMID 9415072): in marmosets, IGF-I and des(1-3)IGF-I were compared across bolus doses of 42 to 270 µg/kg body weight in both anaesthetised and conscious animals; in pigs, doses were 20 and 50 µg/kg for the IGFs against 3 µg/kg for insulin. Serial blood samples ran from 30 minutes before to four hours after injection.

Three things about those numbers limit their transferability. They are per-kilogram, not flat. They were selected to characterise a glucose response rather than to achieve any therapeutic endpoint. And they were given to animals under continuous observation with repeated blood sampling — the monitoring, not the dose, is what made them survivable data points.

The earlier review of the molecule noted that its increased potency is retained only in part in vivo, with anabolic effects most evident in gut tissues, and stated that clinical opportunities for des(1-3)IGF-I had not been evaluated (PMID 8930132). That remains the state of the human evidence.

Bodybuilding and research-community discussion of DES typically cites flat microgram amounts per day, generally in the same band quoted for LR3, sometimes with the added claim that DES should be timed near training because it acts locally and briefly. These figures are anecdotal, unvalidated, and not traceable to any trial. No regulator has defined a safe or effective amount for humans, so there is no authoritative range to anchor against.

The "local action" rationale attached to that timing deserves scrutiny on its own terms: it is an inference from a short half-life, not a demonstrated tissue-targeting property, and the same animal data show DES producing the largest systemic glucose drop of any variant tested.

Community material describes DES as a subcutaneous injection reconstituted from lyophilized powder with bacteriostatic water. Three error modes recur, and for a compound at the top of the potency ranking each one costs more:

• Reconstitution volume sets concentration. The same syringe mark delivers different amounts from differently reconstituted vials, and nothing on the vial verifies either quantity.
• Insulin-syringe units measure volume, not peptide mass. Reading them as micrograms is a routine source of large overdoses.
• Microgram versus milligram — a thousand-fold error separated by one character.

For contrast, the approved recombinant IGF-1 (mecasermin) is dosed in mg/kg twice daily with a defined starting range, a minimum week of tolerance before each escalation step, a hard ceiling, and instructions to reduce the dose if hypoglycemia occurs despite adequate food intake — plus a requirement to administer within ±20 minutes of a meal and to withhold the dose entirely if the patient cannot eat (Increlex label, DailyMed). That is what a controlled dosing structure for an IGF-1 molecule looks like.

DES combines the properties that make self-dosing least forgiving: the highest measured hypoglycemic potency of the IGF variants studied, microgram-scale amounts, an unverified product, and no human data establishing what any dose does. There is no assay to check the vial, no biomarker target to titrate toward, and no monitoring in place when glucose falls. Whether and how such a compound could ever be used is a judgment that belongs to a qualified medical professional.